Clinical trial
Open Label Extension
NCT00172120 · Shire, Industry · Completed
Key facts
| NCT number | NCT00172120 |
|---|---|
| Title | Open Label Extension |
| Official title | An 18-month, Open-label Extension Study of Once-daily ALX1-11 for the Treatment of Postmenopausal Women With Osteoporosis (TRES) |
| Acronym | TRES |
| Lead sponsor | Shire, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Osteoporosis |
| Intervention type | Drug |
| Interventions | ALX1-11 |
| Enrollment | 91 |
| Start date | Jan 10, 2005 |
| Primary completion | Oct 27, 2006 |
| Completion | Oct 27, 2006 |
| First posted | Sep 15, 2005 |
| Last update posted | May 17, 2021 |
| Countries | Argentina, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: